Butantan-DV四价减毒登革疫苗在巴西成人中的安全性和免疫原性:两步双盲随机安慰剂对照2期试验
该2期试验在巴西圣保罗两个中心纳入300名18-59岁健康志愿者,评估Butantan-DV与TV003的安全性和免疫原性。结果显示两者均安全耐受,未观察到严重不良反应,并诱导针对登革病毒1-4型的稳健且均衡的中和抗体应答。
要点
- Butantan-DV和TV003均安全耐受,未观察到严重不良反应。
- 登革病毒未暴露者接种Butantan-DV后,DENV-1至4型血清转化率分别为87%、92%、76%和89%。
- 登革病毒暴露者接种Butantan-DV后,DENV-1至4型血清转化率分别为81%、78%、82%和77%。
核心结论
- Butantan-DV和TV003安全,并诱导针对四种登革病毒血清型的稳健且均衡的中和抗体应答。
研究设计与样本
- 在巴西圣保罗两个临床中心开展的两步、双盲、随机安慰剂对照2期试验,共纳入300名18-59岁健康志愿者。
- A步计划将50名登革病毒未暴露者按2:2:1随机分配接种两剂Butantan-DV、TV003或安慰剂,间隔6个月。
- B步计划将250名登革病毒未暴露和暴露者按4:1随机分配接种一剂Butantan-DV或安慰剂。
主要发现
- 共纳入300人,其中155名(52%)登革病毒未暴露,145名(48%)登革病毒暴露。
- Butantan-DV和TV003均具有免疫原性、耐受良好,未观察到严重不良反应。
- A步中皮疹是最常见不良事件,Butantan-DV组19名参与者中16名(84%)出现,TV003组17名中13名(76%)出现。
- Butantan-DV组和TV003组病毒血症相似。
- Butantan-DV组完成所有血清转化分析访视的85名登革病毒未暴露者中,对DENV-1、DENV-2、DENV-3和DENV-4的血清转化率分别为87%、92%、76%和89%。
临床怎么用
- 该2期试验提示Butantan-DV在成人中安全且免疫原性良好,支持进一步开展效力评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Butantan Institute has manufactured a lyophilised tetravalent live-attenuated dengue vaccine Butantan-DV, which is analogous to the US National Institutes of Health (NIH) TV003 admixture. We aimed to assess the safety and immunogenicity of Butantan-DV. METHODS: We did a two-step, double-blind, randomised placebo-controlled phase 2 trial at two clinical sites in São Paulo, Brazil. We recruited healthy volunteers aged 18-59 years; pregnant women, individuals with a history of neurological, heart, lung, liver or kidney disease, diabetes, cancer, or autoimmune diseases, and individuals with HIV or hepatitis C were excluded. Step A was designed as a small bridge-study between Butantan-DV and TV003 in DENV-naive participants. In step A, we planned to randomly assign 50 dengue virus (DENV)-naive individuals to receive two doses of Butantan-DV, TV003, or placebo, given 6 months apart. In step B, we planned to randomly assign 250 participants (DENV-naive and DENV-exposed) to receive one dose of Butantan-DV or placebo. Participants were randomly assigned, by computer-generated block randomisation (block sizes of five); participants in step A were randomly assigned (2:2:1) to receive Butantan-DV, TV003, or placebo and participants in step B were randomly assigned (4:1) to receive Butantan-DV or placebo. Participants and study staff were unaware of treatment allocation. The primary safety outcome was the frequency of solicited and unsolicited local and systemic adverse reactions within 21 days of the first vaccination, analysed by intention to treat. The primary immunogenicity outcome was seroconversion rates of the DENV-1-4 serotypes measured 91 days after the first vaccination, analysed in the per-protocol population, which included all participants in step A, and all participants included in step B who completed all study visits with serology sample collection. This trial is registered with ClinicalTrials.gov, NCT01696422. FINDINGS: Between Nov 5, 2013, and Sept 21, 2015, 300 individuals were enrolled and randomly assigned: 155 (52%) DENV-naive participants and 145 (48%) DENV-exposed participants. Of the 155 DENV-naive participants, 97 (63%) received Butantan-DV, 17 (11%) received TV003, and 41 (27%) received placebo. Of the 145 DENV-exposed participants, 113 (78%) received Butantan-DV, three (2%) received TV003, and 29 (20%) received placebo. Butantan-DV and TV003 were both immunogenic, well-tolerated, and no serious adverse reactions were observed. In step A, rash was the most frequent adverse event (16 [845] of 19 participants in the Butantan-DV group and 13 [76%] of 17 participants in the TV003 group). Viraemia was similar between the Butantan-DV and TV003 groups. Of the 85 DENV-naive participants in the Butantan-DV group who attended all visits for sample collection for seroconversion analysis and thus were included in the per-protocol analysis population, 74 (87%) achieved seroconversion to DENV-1, 78 (92%) to DENV-2, 65 (76%) to DENV-3, and 76 (89%) to DENV-4. Of the 101 DENV-exposed participants in the Butantan-DV group who attended all visits for sample collection for seroconversion analysis, 82 (81%) achieved seroconversion to DENV-1, 79 (78%) to DENV-2, 83 (82%) to DENV-3, and 78 (77%) to DENV-4. INTERPRETATION: Butantan-DV and TV003 were safe and induced robust, balanced neutralising antibody responses against the four DENV serotypes. Efficacy evaluation of the Butantan-DV vaccine is ongoing. FUNDING: Intramural Research Program US NIH National Institute of Allergy and Infectious Diseases, Brazilian National Bank for Economic and Social Development, Fundação de Amparo à Pesquisa do Estado de São Paulo, and Fundação Butantan.
引用
- Kallas EG, Precioso AR, Palacios R, et al. Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial. Lancet Infect Dis. 2020. PMID: 32220283. doi:10.1016/S1473-3099(20)30023-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。